

Interdisciplinary COPD intervention in primary care: a cluster randomised controlled trial

Liang, Jenifer; Abramson, Michael J; Russell, Grant; Holland, Anne E; Zwar, Nicholas A; Bonevski, Billie; Mahal, Ajay; Eustace, Paula; Paul, Eldho; Phillips, Kirsten; Cox, Narelle S; Wilson, Sally; George, Johnson

Published in:
The European respiratory journal

DOI:
[10.1183/13993003.01530-2018](https://doi.org/10.1183/13993003.01530-2018)

Licence:
Other

[Link to output in Bond University research repository.](#)

Recommended citation(APA):

Liang, J., Abramson, M. J., Russell, G., Holland, A. E., Zwar, N. A., Bonevski, B., Mahal, A., Eustace, P., Paul, E., Phillips, K., Cox, N. S., Wilson, S., & George, J. (2019). Interdisciplinary COPD intervention in primary care: a cluster randomised controlled trial. *The European respiratory journal*, 53(4), Article 1801530. <https://doi.org/10.1183/13993003.01530-2018>

General rights

Copyright and moral rights for the publications made accessible in the public portal are retained by the authors and/or other copyright owners and it is a condition of accessing publications that users recognise and abide by the legal requirements associated with these rights.

For more information, or if you believe that this document breaches copyright, please contact the Bond University research repository coordinator.

1 **Interdisciplinary COPD intervention in primary care: a cluster randomised controlled**
2 **trial**

Jenifer Liang¹, Michael J Abramson², Grant Russell³, Anne E Holland⁴, Nicholas A Zwar^{5,6},
Billie Bonevski⁷, Ajay Mahal⁸, Paula Eustace⁹, Eldho Paul², Kirsten Phillips¹⁰, Narelle S
Cox¹¹, Sally Wilson^{1,12}, Johnson George^{1,2}

1. Centre for Medicine Use and Safety, Faculty of Pharmacy and Pharmaceutical Sciences, Monash University, Australia
2. Department of Epidemiology and Preventive Medicine, School of Public Health and Preventive Medicine, Monash University, Australia
3. Southern Academic Primary Care Research Unit, Department of General Practice, Monash University, Australia
4. Discipline of Physiotherapy, La Trobe University and Alfred Health, Australia
5. School of Public Health and Community Medicine, University of New South Wales, Australia
6. Faculty of Health Sciences & Medicine, Bond University, Australia
7. School of Medicine and Public Health, University of Newcastle, Australia
8. The Nossal Institute for Global Health, University of Melbourne, Australia
9. Eastern Melbourne PHN (EMPHN), Australia
10. Lung Foundation Australia (LFA), Australia
11. Discipline of Physiotherapy, La Trobe University and Institute for Breathing and Sleep, Australia
12. Department of Infrastructure Engineering, The University of Melbourne, Australia

Corresponding author:

Dr Johnson George

Centre for Medicine Use and Safety, Faculty of Pharmacy and Pharmaceutical Sciences,
Monash University, 381 Royal Parade, Parkville, VIC 3052

Tel: +61 3 9903 9178

Fax: +61 3 9903 9629

e-mail: johnson.george@monash.edu

1 **TAKE HOME MESSAGE**

2 An interdisciplinary model of care for COPD in primary care involving smoking cessation
3 support, home medicines review, and home-based pulmonary rehabilitation did not
4 demonstrate superiority over usual care – low uptake by GPs and patients was a challenge.

5

6

7

8

9

10

11

12

13

14

15

16

17

18

19

20

21

22

23

24

25

26

1 **ABSTRACT**

2 We evaluated the effectiveness of an interdisciplinary, primary care-based model of care for COPD.

3 A cluster randomised controlled trial was conducted in 43 general practices in Australia. Adults with
4 a history of smoking and/or COPD, aged ≥ 40 years with ≥ 2 clinic visits in the previous year were
5 enrolled following spirometric confirmation of COPD. The model of care comprised smoking
6 cessation support, home medicines review (HMR), and home-based pulmonary rehabilitation
7 (HomeBase). Main outcomes included changes in St George's Respiratory Questionnaire (SGRQ)
8 score, COPD Assessment Test (CAT), dyspnoea, smoking abstinence and lung function at six and 12
9 months.

10 We identified 272 participants with COPD (157 intervention, 115 usual care); 49/157 (31%)
11 completed both HMR and HomeBase. Intention-to-treat analysis showed no statistically significant
12 difference in change in SGRQ at six months (adjusted between group difference 2.45 favouring
13 intervention, 95%CI – 0.89 to 5.79). Per protocol analyses showed clinically and statistically
14 significant improvements in SGRQ in those receiving the full intervention compared to usual care
15 (difference 5.22, 0.19 to 10.25). No statistically significant differences were observed in change in
16 CAT, dyspnoea, smoking abstinence or lung function.

17 No significant evidence was found for the effectiveness of this interdisciplinary model of care for
18 COPD in primary care over usual care. Low uptake was a limitation.

19

20

21

22

23

24

25

26

27

28

29

30

1 INTRODUCTION

2 Chronic obstructive pulmonary disease (COPD) is a major public health problem. Symptoms and
3 complications can greatly impair patients' ability to perform activities of daily living and compromise
4 quality of life.

5 Management of COPD involves multiple health professionals for delivery of both pharmacological
6 and non-pharmacological interventions for optimal outcomes. The roles of the general practitioner
7 (GP) and other healthcare professionals in the management of COPD are important.¹ There is a trend
8 towards an interdisciplinary approach to COPD management whereby team members from different
9 disciplines work collaboratively, with a common aim, to set goals, make decisions and share resources
10 and responsibilities.² The team of health professionals from different disciplines, work together with
11 the patient, undertakes assessment, diagnosis, intervention, goal-setting and the development of a care
12 plan.³ Integrated disease management (IDM) requires multidisciplinary input and may be further
13 enhanced with an interdisciplinary approach. Integrated disease management is '*a group of coherent*
14 *interventions designed to prevent or manage one or more chronic conditions using a systematic,*
15 *multidisciplinary approach and potentially employing multiple treatment modalities.*'⁴ A recent
16 Cochrane review of multi-component, multi-professional IDM programs for COPD showed positive
17 effects on disease-specific quality of life, exercise capacity, hospital admissions and length of hospital
18 stay, but not on dyspnoea or lung function.⁵ Additionally, IDM programs have demonstrated positive
19 effects on level of follow-up, pulmonary rehabilitation attendance, self-reported daily activity and
20 disease knowledge.^{6,7} However, recent multi-professional interventions for COPD management in
21 primary care have shown no additional benefit beyond usual care on health-related quality of life
22 (HRQoL).^{6,8,9}

23 Underutilisation of spirometry for diagnosis of COPD, sub-optimal pharmacological treatment, and
24 low referral rates for pulmonary rehabilitation are common challenges in COPD management.¹⁰⁻¹³
25 Smoking cessation remains crucial in COPD prevention and management, with up to 50% of smokers
26 developing clinically significant COPD.¹⁴ Medication adherence and incorrect inhaler technique are
27 known issues in the COPD population.^{15,16} Pharmacist-led interventions in the community setting,
28 involving medication review and patient education, have shown positive impact on inhaler technique
29 and medication adherence.^{17,18} The home medicines review (HMR) service is currently a government
30 funded service in Australia for patients with an identifiable clinical need, at risk of medication
31 misadventure and/or on multiple medications, including inhaler devices. Although benefits for
32 pulmonary rehabilitation in COPD management are well established, access and completion of these
33 programs remain low internationally.¹⁹⁻²¹ Home-based pulmonary rehabilitation programs have been
34 evaluated and shown to provide similar outcomes to conventional centre-based rehabilitation.²²

1 Novel models of care aimed at improving smoking cessation, COPD diagnosis, symptom control, and
2 exacerbation prevention through interdisciplinary interventions may enhance quality of life. Multi-
3 professional programs for COPD in primary care to date have not had explicit regard to the interaction
4 among health professionals delivering smoking cessation support, HMRs and home-based pulmonary
5 rehabilitation. We designed an interdisciplinary consumer-centred intervention where GPs, clinic
6 staff, pharmacists and physiotherapists worked collaboratively, with a common purpose, to set goals,
7 make decisions and share resources and responsibilities in the delivery of care.

8

9 ***Aim***

10 The primary aim was to implement an interdisciplinary model of care (RADICALS – Review of
11 Airway Dysfunction and Interdisciplinary Community-based care of Adult Long-term Smokers) in
12 Australian primary care and evaluate its effectiveness on HRQoL at six months.

13 We hypothesised that a primary care-based interdisciplinary team comprising the patient’s GP, clinic
14 staff, pharmacist and physiotherapist delivering a model of care involving smoking cessation support,
15 HMR and home-based pulmonary rehabilitation, would improve COPD-related HRQoL compared to
16 usual care at six months.

17 Secondary objectives were to determine the uptake of this novel model of care, improve the diagnosis
18 of COPD in those at risk in primary care, assist smokers to quit, and improve symptoms, psychosocial
19 outcomes (anxiety and depression) and lung function of those with COPD at six and 12 months.

1 **METHODS**

We carried out a two-arm, cluster randomised controlled trial. Cluster randomisation minimises the risk of contamination across intervention and usual care groups. The detailed protocol of the trial and baseline cohort characteristics are available elsewhere.^{13, 23} This paper focuses on the effectiveness of RADICALS on primary and secondary outcomes at six and 12 months. The trial was registered with the Australia and New Zealand Clinical Trials Registry (ACTRN12614001155684).

2

3 **Clinic recruitment and randomisation**

4 In brief, group or solo GP clinics with at least 1000 patients on their databases were approached
5 directly or with assistance from primary care organisations. After obtaining signed agreement, clinics
6 were block randomised (block sizes of four and six) to usual care or intervention arms using an
7 externally managed web-based randomisation program. Clinics were notified of their allocation. A
8 baseline survey was completed by clinics to provide basic data, including details related to practice
9 staff, availability of spirometers and staff training undertaken previously.

10

11 **Patient selection and data collection**

12 Trained research assistants (RAs) at each clinic identified potential participants by searching patient
13 databases and contacting them via mail or telephone. Patients were eligible if they were ≥ 40 years
14 old, had ≥ 2 clinic visits during the previous year, and self-reported being a current/ex-smoker (≥ 10
15 pack year smoking history) or those who had a documented diagnosis of COPD on clinic records or
16 were being treated with COPD-specific medications.

17 Participants attended a baseline interview at their clinic after providing written consent. Data
18 collection was undertaken, and case-finding used the hand-held COPD-6[®] device (Vitalograph, Ennis,
19 Ireland).²⁴ Those with forced expiratory volume in 1 second (FEV₁)/forced expiratory volume in 6
20 seconds (FEV₆) < 0.75 ²⁵ were referred for spirometry (Easy on-PC spirometers; ndd Medizintechnik
21 AG, Zürich, Switzerland). Spirometry was performed according to American Thoracic
22 Society/European Respiratory Society guidelines.²⁶ A post-bronchodilator FEV₁/forced vital capacity
23 (FVC) < 0.7 suggested COPD.²⁷ Recent spirometry undertaken outside the trial was assessed, if
24 accessible. An algorithm guided RAs in establishing a diagnosis of COPD (available from authors).
25 Uncertain cases were interpreted by a respiratory scientist and/or respiratory physician. Spirometry
26 results, modified Medical Research Council (mMRC) and COPD Assessment Test (CAT) scores were
27 communicated to each participant's GP/clinic staff for review and confirmation of diagnosis with the
28 patient. Only those participants diagnosed as having COPD were included in the primary
29 effectiveness analysis.

1 **Usual care**

2 GPs in usual care practices continued to provide routine care to their patients. Copies of the COPD-X
3 Plan²⁸ and the Smoking Cessation guide²⁹ were provided to clinic staff. Spirometry results and
4 interpretation were made available for GPs to review. Participants were given the Lung Foundation
5 Australia booklet '*Better Living with Chronic Obstructive Pulmonary Disease – A Patient Guide*'.³⁰

6
7 **Intervention**

8 The RADICALS model of care was underpinned by Australian COPD-X guidelines.²⁷

9 In addition to usual care, GPs and other staff from intervention group practices were offered training
10 on spirometry and the COPD-X guidelines ²⁸, and a smoking cessation guide.²⁹

11 The RADICALS model of care comprised the following:

12 *Individualised smoking cessation support* was provided to smokers using QUIT resources and guided
13 by a treatment algorithm.³¹ This consisted of brief counselling and Quitline referral provided by RAs
14 during baseline interview to all smokers in the intervention arm, regardless of COPD diagnosis.

15 Over-the-counter and/or prescription medications for smoking cessation were also recommended, if
16 appropriate.

17 The *home medicines review (HMR)*³² was performed by an accredited consultant pharmacist and
18 consisted of an interview with participants in their homes (approximately 1.5 hours). The interview
19 allowed the pharmacist to assess medication use and participants' knowledge about their medications
20 (including inhaler use and technique), provide education focusing on medication use, and further
21 individualised smoking cessation support, if relevant. A report was subsequently generated by the
22 pharmacist and forwarded to the participant's GP outlining recommendations for optimising
23 medication use, especially for COPD.

24 The *eight-week home-based pulmonary rehabilitation (HomeBase) program*²², delivered by a
25 specifically trained physiotherapist, consisted of one home visit and weekly follow-up telephone calls.
26 Home-based aerobic and resistance exercise training was individually prescribed. Telephone calls
27 employed motivational interviewing principles to achieve disease-specific self-management training
28 and exercise progression.

29 The model of care was coordinated by the RA at each site under the supervision of each participant's
30 GP and clinic staff. Consenting patients were referred by the GP, at their discretion, to HomeBase and
31 HMR. Following real-world practice, normal processes of spirometry results review and patient
32 consent for service referrals occurred.

1 **Follow-up**

2 Participants were followed at six and 12 months after baseline by RAs blinded to clinic and group
3 allocation. Follow-ups (telephone and/or face-to-face) involved completion of a structured
4 questionnaire with outcomes of interest, post-bronchodilator spirometry testing and exhaled carbon
5 monoxide (eCO) testing in smokers (if self-reported not smoking in the previous seven days).

6

7 **Outcomes and measurements**

8 The primary outcome was change in the overall HRQoL, measured using St George's Respiratory
9 Questionnaire (SGRQ)³³ score, at six months from baseline.

10 Secondary outcomes measured in participants at six and 12 months from baseline included changes
11 in: (1)SGRQ score³³ (at 12 months); (2) CAT score³⁴; (3) mMRC grade^{35, 36}; (4) Lung function
12 (FEV₁ % predicted)³⁷; (5) Hospital Anxiety and Depression Scale (HADS) score^{38, 39}; (6) Heaviness of
13 Smoking Index (HSI) score⁴⁰; (7) Proportions of COPD participants with biochemically verified
14 seven-day point prevalence smoking abstinence – eCO levels were measured using a handheld piCO
15 Smokerlyzer (Bedfont Scientific, Maidstone, Kent, UK) to confirm self-report of seven-day point
16 prevalence abstinence (a participant with CO level \leq 6 parts per million (ppm) was considered
17 abstinent; missing data for smoking-related outcomes were treated in accordance with the Russell
18 standard⁴¹, whereby a smoker lost to follow-up was considered to have continued to smoke).

19 Process outcomes including the uptake of the HMR and HomeBase by GPs and participants, and
20 inhaler-related issues identified during HMR, were measured by reviewing participant logs and notes
21 recorded by the HMR pharmacist and HomeBase physiotherapists delivering these services.

22 Description of each outcome measure is included in the published study protocol.²³

23

24 **Sample size**

25 Change in SGRQ score at six months from baseline was the primary effectiveness endpoint. A
26 difference of at least four points in SGRQ between treatment arms was considered clinically
27 significant.³³ Assuming a standard deviation (SD) of 10 points in SGRQ, 99 participants per group
28 (80% power, $\alpha=0.05$) were needed to detect this. The required sample was 108 per arm (intra-class
29 correlation=0.01⁴², cluster size=10). At least 28 primary care practices need to be recruited and 14
30 each randomised to intervention and usual care arms. Further details have been previously
31 published.²³

32

1 **Statistical analysis**

2 Analyses were conducted in accordance with a predefined analysis plan.²³ Baseline characteristics of
3 the intervention and control groups were summarised according to data type and distribution.

4 Outcomes were assessed at the participant level. All regression analyses were adjusted for clustering,
5 age, education, income, current smoking status and prior COPD diagnosis. The effectiveness analysis
6 was according to an intention-to-treat principle. Mean change in SGRQ score at six months in each
7 treatment group was estimated. Differences between groups and the corresponding 95% confidence
8 intervals (CI) were determined. Multivariable analysis was performed using multiple linear
9 regression, adjusting for baseline imbalances and confounders. Multiple imputation was generated for
10 missing data based on the assumption that data were from a multivariate normal distribution and were
11 missing at random. The regression method was used for imputation with 10 imputed datasets used for
12 each variable.

13 Per-protocol analyses (pre-defined) were also conducted to determine effectiveness within
14 participants completing the intervention as intended. Completion of HomeBase was defined as
15 completion of a minimum of 70% of total sessions (i.e. at least six out of eight sessions in the
16 program).²² Completion of HMR was defined as having been present at a pre-booked appointment and
17 participating in an interview with the consultant pharmacist. Therefore, intervention group
18 participants were categorised according to their degree of completeness: '*full intervention*'
19 (Completion of both HMR and HomeBase), '*partial intervention*' (HMR only, HomeBase only,
20 partial HomeBase only, or HMR and partial HomeBase) or '*no intervention*'. Baseline participant
21 characteristics were compared between (1) those who completed the full intervention and those who
22 did not; and (2) those who completed the trial and those who were lost to follow-up. Differences in
23 baseline clinic characteristics were determined for those clinics with at least one participant
24 completing the full intervention and those clinics with no full intervention completers.

25 All analyses were performed using Statistical Package for Social Sciences (SPSS) (version 24.0; IBM,
26 Armonk, NY) or Stata version 14.0 (StataCorp, College Station, TX).

27

28

29

30

31

32

1 **RESULTS**

2 A total of 43 clinics were randomised to intervention (n=21) or usual care (n=22); two clinics
3 randomised to the usual care arm withdrew before recruiting any participants (Figure 1).

4 Characteristics of clinics have been previously described.¹³ Between February 2016 and April 2017, a
5 total of 1050 participants were recruited (618 from intervention clinics and 432 from usual care
6 clinics), of whom 272 were confirmed to have COPD (157 from intervention clinics and 115 from
7 usual care clinics). At baseline, the groups appeared similar, although intervention group participants
8 were older and more likely to have a trade rather than university education, but less likely to be
9 current smokers than the usual care group (Table 1).

10 The drop-out rates at 12 month follow-up were similar (intervention group 44/157 [28%] compared to
11 38/115 [33%] in usual care, p=0.45). Participants who completed the 12 month follow-up were older,
12 more likely to be in a relationship, not living independently and had better lung function (i.e. higher
13 FEV₁ %predicted) compared to those who dropped out (Supplementary file).

14

15 **Table 1: Baseline demographic and clinical characteristics**

Characteristic	Usual Care (n=115, 16 clinics)	Intervention (n=157, 19 clinics)
Age, mean (SD)	61.7 (10.1)	66.6 (10.8)
Gender, male	72 (62.6%)	95 (60.5%)
Born in Australia^a	86 (74.8%)	114 (74.0%)
Mainly speak English at home	113 (98.3%)	154 (98.1%)
Education^a		
No formal schooling/up to primary school/primary school	4 (3.5%)	14 (9.1%)
High school	63 (54.8%)	68 (44.2%)
Technical/further education	22 (19.1%)	51 (33.1%)
University education/postgraduate	26 (22.6%)	21 (13.6%)
Employment status^a		
Employed-full/part-time/casual	25 (22.3%)	51 (32.5%)
Retired/pensioner	68 (60.7%)	84 (53.5%)
Unemployed/home duties/student/unable to work/disabled	19 (17.0%)	22 (14.0%)
Marital status^a		
Married/de-facto/engaged	53 (46.1%)	69 (44.8%)
Separated/divorced/widowed/never married/single	61 (53.0%)	85 (55.2%)
Undisclosed	1 (0.9%)	0 (0.0%)
Current living arrangements^a		
With family/friends/spouse/partner	76 (66.1%)	97 (63.0%)
Alone at home	36 (31.3%)	51 (33.1%)
Shared accommodation/community housing/refuge accommodation/residential facility/residential aged care facility	3 (2.6%)	6 (3.9%)
Average annual household income^b		

<AUD \$30,000	45 (40.2%)	74 (49.7%)
AUD \$30,000-\$59,999	25 (22.3%)	32 (21.5%)
AUD \$60,000 or more	18 (16.1%)	31 (20.8%)
Did not want to disclose	24 (21.4%)	12 (8.1%)
Previously managed as having COPD	56 (48.7%)	74 (47.1%)
Currently smoking	82 (71.3%)	84 (53.5%)
Heaviness of Smoking Index score^c		
Low nicotine dependence (score 0-2)	24 (29.3%)	21 (26.3%)
Moderate nicotine dependence (score 3-4)	46 (56.1%)	44 (55.0%)
High nicotine dependence (score 5-6)	12 (14.6%)	27 (16.7%)
Post-bronchodilator FEV₁ %predicted, mean (SD)^a	70.8 (19.3)	69.0 (20.5)
Post-bronchodilator FEV₁ / FVC, mean (SD)^a	0.57 (0.10)	0.57 (0.13)
Disease severity^{a,d}		
Mild	82 (71.9%)	108 (69.7%)
Moderate	26 (22.8%)	30 (19.4%)
Severe	6 (5.3%)	17 (11.0%)
mMRC dyspnoea grade^e		
Grade 0	39 (34.2%)	37 (23.6%)
Grade 1	42 (36.8%)	70 (44.6%)
Grade 2	22 (19.3%)	26 (16.6%)
Grade 3	10 (8.8%)	21 (13.4%)
Grade 4	1 (0.9%)	3 (1.9%)
^a missing data for 3 participants ^b missing data for 11 participants; Australian annual pension rate for singles is ~\$24,000 ^c missing data for 4 participants ^d severity of COPD based on COPD-X Plan; FEV ₁ % predicted values (60-80% predicted = mild, 40-59% predicted = moderate, <40% predicted = severe) ²⁸ ; 80 participants had FEV ₁ % values>80% but had characteristic symptoms of mild COPD ^e missing data for 1 participant COPD = Chronic Obstructive Pulmonary Disease; FEV ₁ = Forced Expiratory Volume in 1 second; FVC = Forced Vital Capacity; SD = Standard Deviation; IQR = Interquartile Range; mMRC = modified Medical Research Council		

1

2

3 **Primary outcome**

4 SGRQ scores improved in both groups between baseline and six months, however only the change in
5 SGRQ score within the intervention group was statistically significant (3.07; 95%CI 0.73 to 5.42)
6 (Table 2). Difference in SGRQ score changes between groups was not statistically significant
7 (adjusted mean difference 2.45 favouring intervention, 95%CI -0.89 to 5.79) at six months (Table 2).
8 Multiple imputation analyses performed for missing SGRQ data showed similar results
9 (Supplementary Table 1). No statistically significant differences in proportions of participants
10 achieving the minimum clinically important difference (MCID) in SGRQ of four or more were
11 observed between groups (intervention: 47/105 [44.8%]; usual care: 38/90 [42.2%]) (data not shown).

12

1 **Secondary outcomes**

2 *Six-month outcomes*

3 Changes in CAT and lung function (FEV₁% predicted) from baseline at six months between groups
4 were not statistically significant (Table 3). There were no differences in HSI scores (median 3 [IQR 2-
5 4] in both groups, p=0.62) and proportion of smokers with biochemically-verified seven-day point
6 prevalence smoking abstinence (intervention: 6/84 [7.1%]; usual care: 3/82 [3.7%]; p=0.50) between
7 groups at six months. Multiple imputation analyses performed for missing CAT and FEV₁% predicted
8 data showed similar results (Supplementary Table 1). Proportions of participants who showed
9 improvements (from baseline) in HADS anxiety/depression scores and mMRC grades were not
10 significantly different between groups (Table 3).

11

12 *12-month outcomes*

13 No statistically significant differences between groups in change in SGRQ, CAT, proportions of
14 participants achieving SGRQ MCID (data not shown), and those showing improvements (from
15 baseline) in HADS anxiety/depression scores and mMRC grades (Table 2 and 3). Multiple imputation
16 analyses performed for missing SGRQ and CAT outcome data showed similar results (Supplementary
17 Table 1). Spirometry was repeated only in those attending a face-to-face follow-up interview (6% of
18 participants); smoking abstinence outcomes were restricted to those reporting abstinence at six
19 months.

20

21 *Process outcomes*

22 Uptake of the intervention was poor. Only 31% (49/157) completed the full intervention, a quarter
23 (26%, 41/157) partially completed the intervention [HMR only (19/40), Homebase program only
24 (6/40), HMR and partially completed Homebase program (13/40), partially completed Homebase
25 program only (3/40)]; and 67 participants (43%) did not receive any part of the intervention. Reasons
26 for not receiving the intervention included GP non-referral, participant uncontactable for
27 appointments, declining exercise, lack of perceived need for HMR, being too busy and declining due
28 to personal/family circumstances. Of the COPD participants referred and eventually completing the
29 HMR, 35/81 (43%) were assessed as having suboptimal inhaler technique and 70/81 (86%)
30 participants were provided demonstration of their inhaler devices by the visiting HMR pharmacist.

31 There were no significant differences in baseline characteristics between clinics that had at least one
32 participant completing the full intervention versus clinics that had no participant completing the full
33 intervention (Supplementary file). Those participants who received the full intervention were more

- 1 likely to be in a relationship, and had higher SGRQ and CAT scores (i.e. lower quality of life)
- 2 compared to those who did not receive the full intervention (Supplementary file).

1 **Table 2. SGRQ score differences from baseline to six and 12 months – Intention to treat (ITT) analysis**

Outcome	Baseline, mean (SD)		Within group change at 6 months, mean (95% CI)		Between group difference at 6 months, mean (95% CI) ^b	Within group change at 12 months, mean (95% CI)		Between group difference at 12 months, mean (95% CI) ^b
	Usual care (n=115)	Intervention (n=157)	Usual care	Intervention		Usual care	Intervention	
SGRQ score ^a	31.34 (18.38)	32.66 (17.94)	1.54 (-1.06, 4.14)	3.07 (0.73, 5.42)	2.45 (-0.89, 5.79) P = 0.15	3.35 (0.57, 6.14)	4.69 (1.96, 7.41)	2.21 (-2.86, 7.28) P = 0.38

2 ^a n=258 at baseline, n=204 at 6 months and n= 185 at 12 months respectively.

3 ^b Adjusted for clustering, age, highest education, gross income, current smoking status, and existing COPD

4 CI=confidence interval; ITT=intention to treat; SD=standard deviation; SGRQ=St George's Respiratory Questionnaire

5

6 **Table 3. CAT, lung function, mMRC grade and HADS score differences from baseline to six and 12 months**

Outcome	Baseline, mean (SD)		Within group change at 6 months, mean (95% CI)		Between group difference at 6 months, mean (95% CI) ^c	Within group change at 12 months, mean (95% CI)		Between group difference at 12 months, mean (95% CI) ^c
	Usual care (n=115)	Intervention (n=157)	Usual care	Intervention		Usual care	Intervention	
CAT score ^a	13.57 (7.94)	12.94 (7.57)	1.50 (0.56, 2.44)	2.06 (0.87, 3.26)	0.66 (-1.98, 3.30) P = 0.61	2.62 (1.58, 3.67)	3.05 (1.80, 4.31)	0.86 (-2.02, 3.74) P = 0.55
Post-bronchodilator FEV ₁ , % predicted ^b	70.82 (19.27)	68.98 (20.46)	-0.09 (-1.84, 1.67)	0.79 (-0.86, 2.44)	1.09 (-1.59, 3.76) P = 0.41	NA	NA	NA
	Baseline, median [IQR]		6 month follow-up, median [IQR]; participants showing improvement ^h (%)			12 month follow-up, median [IQR]; participants showing improvement ^h (%)		
	Usual care (n=115)	Intervention (n=157)	Usual care	Intervention	p-value ^g	Usual care	Intervention	p-value ^g
mMRC grade ^d	1 [0-2]	1 [1-2]	1 [1-2]; 17.0%	1 [1-2]; 23.7%	0.31	1 [0-2]; 18.2%	1 [1-2]; 21.2%	0.74

HADS anxiety score^e	7 [3-9]	6 [3-9]	3 [0-6]; 69.8%	2 [0-5]; 70.8%	1.00	0 [0-3]; 87.1%	1 [0-4]; 80.0%	0.32
HADS depression score^f	4 [2-7]	5 [2-7]	1 [0-4]; 72.0%	1 [0-4]; 71.2%	1.00	0 [0-1.25]; 85.3%	1 [0-3.25]; 77.0%	0.30

1 ^a n=271 at baseline, n=208 at 6 months and n= 189 at 12 months respectively.

2 ^b n=269 at baseline and n=185 at 6 months respectively.

3 ^c Adjusted for clustering, age, highest education, gross income, current smoking status, existing COPD

4 ^d n=271 at baseline, n=208 at 6 months and n=190 at 12 months respectively

5 ^e n=264 at baseline, n=186 at 6 months and n=170 at 12 months respectively

6 ^f n=264 at baseline, n=190 at 6 months and n=172 at 12 months respectively

7 ^g p-value of between group differences in proportion of participants showing improvement in grade/score

8 ^h follow-up grade/score lower than baseline grade/score indicated improvement

9

10 CAT=COPD Assessment Test; CI=confidence interval; FEV₁=forced expiratory volume in 1 second; HADS=Hospital Anxiety and Depression Scale;

11 ITT=intention to treat; IQR=Interquartile Range; mMRC=modified Medical Research Council; NA= not available; SD=standard deviation

12

1 **Exploratory Per Protocol Analysis (PPA)**

2 An exploratory PPA was performed to assess the effect of the intervention in those who received the
3 full intervention as intended. Statistically and clinically significant differences in change in SGRQ
4 score at six months were observed within the intervention group (5.66; 95%CI 1.91 to 9.42), and
5 when compared to usual care (adjusted mean difference 5.22; 95%CI 0.19 to 10.25; p=0.042)
6 (Supplementary Table 2). The improvement in SGRQ score in the intervention group was more
7 pronounced and sustained at 12 months; the between group difference was clinically, but not
8 statistically significant. Multiple imputation analyses confirmed these patterns (Supplementary Table
9 3). More than half (23/42, 55%) of the full intervention group participants improved their SGRQ by
10 the MCID or greater at six months (data not shown). Although changes in CAT score were more
11 pronounced in the intervention group (at six and 12 months), between group differences in CAT
12 scores and FEV₁% predicted (at six months only) were not statistically significant.

13

14 **DISCUSSION**

15 Our results showed no significant evidence for the effectiveness of an interdisciplinary model of care
16 in primary care involving smoking cessation support, home medicines review and home-based
17 pulmonary rehabilitation beyond usual care at improving HRQoL, symptom severity or lung function
18 in a cohort of patients with predominantly mild COPD. Nevertheless, an improvement in mean
19 SGRQ score was evident within the intervention group. Exploratory analyses of those who received
20 the intended full intervention showed statistically and clinically significant differences over usual care
21 at six months, and the benefits within the full intervention group were sustained at 12 months.
22 However, uptake of the intended intervention components by both GPs and patients was suboptimal.

23 The effectiveness of integrated disease management programs in COPD is still uncertain. While a
24 recent Cochrane review showed positive effects of these interventions on HRQoL,⁷ there was
25 considerable heterogeneity between the included studies, mainly due to differences in the healthcare
26 systems where these trials took place.⁴³ Our interdisciplinary model coordinated by the patient's GP
27 could not achieve fully integrated care due to a range of patient-, health professional- and health
28 system-related factors. Our findings concur with recent studies of primary care-based COPD
29 management programs targeting those with relatively mild disease in Australia, the Netherlands, and
30 Switzerland, which showed no additional benefit of disease management and health professional
31 partnership programs on HRQoL over usual care.⁷⁻⁹

32 More specifically, our results are similar to the primary-care based COPD management program of
33 Kruis et al conducted in the Netherlands, however there were some key differences in the intervention
34 design. Kruis et al offered an intervention consisting primarily of intensive training provided to GPs,

1 nurses and physiotherapists on how to implement integrated disease management in practice, whereas
2 RADICALS had a GP-coordinated interdisciplinary intervention where every GP and participant in
3 the intervention arm was offered the intervention comprising smoking cessation support, HMR and
4 home-based pulmonary rehabilitation. Our study also included a case-finding component for
5 optimising the diagnosis of COPD in primary care. The study population comprised many newly
6 diagnosed patients who had mild disease.¹³ Low baseline SGRQ scores, low mMRC scores, and mild
7 disease based on FEV₁ %predicted²⁸ may explain the small effect observed. A 'floor effect' is a
8 possible explanation for the minimal changes observed in SGRQ, other quality of life scores and
9 dyspnoea.^{6, 8, 9} It is likely that COPD was not a priority for either GPs or participants for discussions
10 during consultations and for subsequent interventions if patients had only mild symptoms, explaining
11 the modest uptake of the interventions in this group.

12 Although the change in SGRQ in our trial was minimal, the magnitude of change in SGRQ in the
13 intervention arm at six and 12 months is on par with a recent large clinical trial of combination
14 pharmacotherapies in patients with moderate to very severe COPD.⁴⁴ The interventions delivered in
15 our study model are services or resources that are readily available and could be complementary to
16 pharmacological treatments for COPD, if implemented early and more widely. This model could
17 potentially be more effective in primary care by targeting those with symptoms and with better
18 intervention fidelity.

19 Participation in pulmonary rehabilitation has been shown to improve HRQoL in patients with
20 COPD.²⁰ The HomeBase program in the RADICALS model is equivalent to centre-based pulmonary
21 rehabilitation at improving HRQoL for patients with moderate to severe disease.²² However, the
22 effectiveness of pulmonary rehabilitation programs for mild COPD is still uncertain.⁴⁵ The majority of
23 our trial population had low levels of activity limitation (most participants self-reported low mMRC
24 grades), and therefore may not have recognised the need for the intervention.

25 The roles of pharmacists in COPD management and positive effects of interventions on medication-
26 adherence and inhaler technique have been previously shown.¹⁸ Such advice was routinely provided to
27 participants by the pharmacist during the HMR. Due to the large number of practices and GPs
28 involved, it was not possible to ensure that pharmacist recommendations were implemented by GPs,
29 which may have diminished the effect.

30

31 ***Strengths and limitations***

32 The key strength of this study was the assessment of real-world effectiveness of an interdisciplinary
33 model of care comprising resources and services readily accessible in primary care. Multiple clinics
34 and GPs were recruited into the study; clinics varied in size, availability of respiratory services, and

1 socio-economic status of the clientele, increasing the generalisability of our findings. Cluster
2 randomisation minimised the risk of contamination associated with the same practice staff treating
3 participants from different trial arms. Although there was the potential for Hawthorne effect in this
4 open-label study (participants and health professionals were not blinded), outcome assessments were
5 performed by RAs blinded to group allocation.

6 Practice and participant recruitment was challenging. The numbers of clinics and participants in the
7 two arms were unbalanced and not all clinics contributed to the COPD cohort. Attrition rates were
8 slightly higher than originally anticipated, also contributing to the small effects observed; those who
9 completed all follow-ups may not be representative of the wider COPD population, especially those
10 with mild or no symptoms. Greater variability in SGRQ scores was seen due to recruitment of
11 subjects with any severity of COPD. We did not assess changes in pharmacological or non-
12 pharmacological COPD management in usual care participants. We also could not tell whether
13 participants undertook traditional hospital outpatient pulmonary or received HMR (both existing
14 services in Australia) during the study through other sources. Trial effects, dissemination of COPD-X
15 and smoking cessation guidelines, lung function testing and provision of spirometry results to GPs in
16 the usual care arm, might have prompted changes in COPD management in these participants, which
17 would not have otherwise occurred. We did not assess changes in participant behaviours such as
18 adherence to medication, inhaler technique and adherence to home exercises.

19 A key limitation is the low uptake of the intervention components. Due to logistical and resource
20 limitations, we did not organise interviews with patients, practice managers or GPs to obtain more
21 information on process outcomes and detailed reasons for the low uptake. Although per-protocol
22 analyses revealed statistically significant changes in SGRQ at six months, this standalone positive
23 outcome should be interpreted with caution. Most importantly, poor uptake of the intervention does
24 not allow us to interpret whether the negative findings were resultant from being unable to deliver the
25 intervention or from intervention failure.

26

27 *Practice implications and future research*

28 Challenges in implementation and slow uptake of the non-pharmacological interventions offered
29 within this pragmatic trial are important lessons for future primary care studies. There were delays in
30 delivering the multi-component intervention due to the multiple steps involved e.g. spirometry results
31 review (with or without expert input in interpretation and diagnosis), organising of patient visits to
32 discuss results, eventual referral to HMR and/or HomeBase by GP following patient consent, and GP
33 follow-up visit to implement pharmacist HMR report recommendations. Efforts made to educate GPs
34 and participants on the potential benefits of HMR and HomeBase did not necessarily translate to
35 referral and/or uptake. Although the clinic management agreed to participate in the trial, not all GPs

1 practising within each clinic actively supported trial implementation. Limited resources for delivering
2 the intervention at the clinic level due to competing demands for GPs' time and inadequate
3 remuneration for delivering the service might have been barriers. Lack of implementation fidelity can
4 make interventions appear to be ineffective.⁴⁶

5 Future studies should factor in the real-world challenges of recruitment, time considerations, and
6 diagnostic and referral processes in the primary care setting. Specific training on integrated disease
7 management concepts provided to health professionals involved should be considered and may
8 potentially increase delivery of integrated care in practice.

9 Where possible, a phased approach to intervention development with preliminary testing (including
10 collecting information on reasons for non-referral to intervention components) should be conducted to
11 inform feasibility and level of uptake of interventions by GPs and participants. Engagement of
12 individual GPs, a more proactive and streamlined intervention referral process, detailed explanation of
13 the disease and its effects to patients, and the potential benefits of non-pharmacological interventions
14 such as HomeBase and HMRS may improve participant interest and intervention uptake.

15 In primary care, uptake of and adherence to healthy behaviours (smoking cessation, increased
16 physical activity) and self-management skills (optimal use of inhaled medications, and early
17 recognition and treatment of worsening of symptoms) may be better predictors of longer-term
18 outcomes in patients with mild disease. Patient needs, preferences and personal goals should be
19 carefully assessed and considered to inform subsequent intervention program tailoring.

20

21

22 **ACKNOWLEDGEMENTS**

23 We wish to thank all our funding bodies and partner organisations for supporting the trial (BI,
24 EMPHN, LFA, and NHMRC). BB is supported by an Australian National Health and Medical
25 Research Council Career Development Fellowship (GNT1063206) and a Faculty of Health and
26 Medicine, University of Newcastle Gladys M Brawn Career Development Fellowship. JL is the
27 recipient of the Cyril Tonkin Scholarship 2014 (Victorian College of Pharmacy Foundation Board,
28 Monash University). We wish to thank Data Safety and Monitoring Board members (Prof Ian Yang,
29 Prof Jennifer Alison, Dr Julia Walters), Denise van den Bosch, Jessica Webster, Rita Breare, Mieke
30 Hutchinson-Kern, Eleonora Del Colle and Pulmetrics staff, Brian Meier, Agape Stratigis, Amanda
31 Cross, Amanda Nichols, Andrew Clayton, Caroline Nicolson, Francesca Sgroi, Georgia Lakoumentas,
32 Hilary Edwards, Janet Carberry, Jannette Angell, Kay Dunkley, Lisa Austin, Melanie Fordsham,
33 Robyn Saunders, Robyn Stell, Dr Ross de Gori, Rosemary Moore, Sandy Scholes, Sarah Rawlings,
34 Tamara Ford, Yamuna Prashanth, research students, clinic staff and participants.

1 **AUTHOR CONTRIBUTIONS**

2 JG conceived the research idea and developed it with input from chief investigators MJA, GR, NAZ,
3 AEH, BB and AM. Representatives of partner organisations (KP and PE) contributed to discussions.
4 JL is a PhD student working under the supervision of MJA and JG. JL coordinated data collection
5 and data management. EP and JL carried out statistical analyses required for the manuscript. SW was
6 the project manager responsible for the recruitment of clinics and the overall conduct of the study.
7 NSC coordinated delivery of the HomeBase program. JL drafted the original manuscript draft. All
8 authors contributed to data interpretation and manuscript revision, and provided approval of the final
9 manuscript.

10

11

12 **REFERENCES**

- 13 1. Schermer T, van Weel C, Barten F, Buffels J, Chavannes N, Kardas P, et al. Prevention and
14 management of chronic obstructive pulmonary disease (COPD) in primary care: position
15 paper of the European Forum for Primary Care. *Qual Prim Care*. 2008;16(5):363-77.
16 2. Victorian Government Department of Health Services. Health independence programs
17 guidelines. Melbourne, Australia. 2008.
18 3. Jessup RL. Interdisciplinary versus multidisciplinary care teams: do we understand the
19 difference? *Aust Health Rev*. 2007;31(3):330-1.
20 4. Schrijvers G. Disease management: a proposal for a new definition. *Int J Integr Care*.
21 2009;9:e06.
22 5. Kruis AL, Smidt N, Assendelft WJ, Gussekloo J, Boland MR, Rutten-van Molken M, et al.
23 Integrated disease management interventions for patients with chronic obstructive
24 pulmonary disease. *Cochrane Database Syst Rev*. 2013(10):CD009437.
25 6. Zwar NA, Hermiz O, Comino E, Middleton S, Vagholkar S, Xuan W, et al. Care of patients with
26 a diagnosis of chronic obstructive pulmonary disease: a cluster randomised controlled trial.
27 *Med J Aust*. 2012;197(7):394-8.
28 7. Kruis AL, Boland MR, Assendelft WJ, Gussekloo J, Tsiachristas A, Stijnen T, et al. Effectiveness
29 of integrated disease management for primary care chronic obstructive pulmonary disease
30 patients: results of cluster randomised trial. *BMJ* 2014;349:g5392.
31 8. Markun S, Rosemann T, Dalla-Lana K, Steurer-Stey C. Care in Chronic Obstructive Lung
32 Disease (CAROL): a randomised trial in general practice. *Eur Respir J*. 2018;51(5).
33 9. Zwar NA, Bunker JM, Reddel HK, Dennis SM, Middleton S, van Schayck OC, et al. Early
34 intervention for chronic obstructive pulmonary disease by practice nurse and GP teams: a
35 cluster randomized trial. *Fam Pract*. 2016;33(6):663-70.
36 10. Price D, West D, Brusselle G, Gruffydd-Jones K, Jones R, Miravittles M, et al. Management of
37 COPD in the UK primary-care setting: an analysis of real-life prescribing patterns. *Int J Chron
38 Obstruct Pulmon Dis*. 2014;9:889-904.
39 11. Bourbeau J, Sebaldt RJ, Day A, Bouchard J, Kaplan A, Hernandez P, et al. Practice patterns in
40 the management of chronic obstructive pulmonary disease in primary practice: the CAGE
41 study. *Can Respir J*. 2008;15(1):13-9.
42 12. Jones RC, Dickson-Spillmann M, Mather MJ, Marks D, Shackell BS. Accuracy of diagnostic
43 registers and management of chronic obstructive pulmonary disease: the Devon primary
44 care audit. *Respir Res*. 2008;9:62.

- 1 13. Liang J, Abramson MJ, Zwar NA, Russell GM, Holland AE, Bonevski B, et al. Diagnosing COPD
2 and supporting smoking cessation in general practice: evidence-practice gaps. *Med J Aust.*
3 2018;208(1):29-34.
- 4 14. Lundback B, Lindberg A, Lindstrom M, Ronmark E, Jonsson AC, Jonsson E, et al. Not 15 but
5 50% of smokers develop COPD?--Report from the Obstructive Lung Disease in Northern
6 Sweden Studies. *Respir Med.* 2003;97(2):115-22.
- 7 15. George J, Kong DC, Thoman R, Stewart K. Factors associated with medication nonadherence
8 in patients with COPD. *Chest.* 2005;128(5):3198-204.
- 9 16. Lareau SC, Yawn BP. Improving adherence with inhaler therapy in COPD. *Int J Chron Obstruct*
10 *Pulmon Dis.* 2010;5:401-6.
- 11 17. Hesso I, Gebara SN, Kayyali R. Impact of community pharmacists in COPD management:
12 Inhalation technique and medication adherence. *Respir Med.* 2016;118:22-30.
- 13 18. van der Molen T, van Boven JF, Maguire T, Goyal P, Altman P. Optimizing identification and
14 management of COPD patients - reviewing the role of the community pharmacist. *Br J Clin*
15 *Pharmacol.* 2017;83(1):192-201.
- 16 19. Brooks D, Sottana R, Bell B, Hanna M, Laframboise L, Selvanayagarajah S, et al.
17 Characterization of pulmonary rehabilitation programs in Canada in 2005. *Can Respir J.*
18 2007;14(2):87-92.
- 19 20. McCarthy B, Casey D, Devane D, Murphy K, Murphy E, Lacasse Y. Pulmonary rehabilitation
20 for chronic obstructive pulmonary disease. *Cochrane Database Syst Rev.* 2015(2):CD003793.
- 21 21. Yohannes AM, Connolly MJ. Pulmonary rehabilitation programmes in the UK: a national
22 representative survey. *Clin Rehabil.* 2004;18(4):444-9.
- 23 22. Holland AE, Mahal A, Hill CJ, Lee AL, Burge AT, Cox NS, et al. Home-based rehabilitation for
24 COPD using minimal resources: a randomised, controlled equivalence trial. *Thorax.*
25 2017;72(1):57-65.
- 26 23. Liang J, Abramson MJ, Zwar N, Russell G, Holland AE, Bonevski B, et al. Interdisciplinary
27 model of care (RADICALS) for early detection and management of chronic obstructive
28 pulmonary disease (COPD) in Australian primary care: study protocol for a cluster
29 randomised controlled trial. *BMJ Open.* 2017;7(9):e016985.
- 30 24. Lung Foundation Australia. COPD screening using the COPD-6 [cited 2017 Oct]. Available
31 from: [https://lungfoundation.com.au/wp-content/uploads/2014/02/Instruction-sheet-Piko-](https://lungfoundation.com.au/wp-content/uploads/2014/02/Instruction-sheet-Piko-6-and-COPD-6.pdf)
32 [6-and-COPD-6.pdf](https://lungfoundation.com.au/wp-content/uploads/2014/02/Instruction-sheet-Piko-6-and-COPD-6.pdf)
- 33 25. Frith P, Crockett A, Beilby J, Marshall D, Attewell R, Ratnanesan A, et al. Simplified COPD
34 screening: validation of the PiKo-6(R) in primary care. *Prim Care Respir J.* 2011;20(2):190-8.
- 35 26. Miller MR, Hankinson J, Brusasco V, Burgos F, Casaburi R, Coates A, et al. Standardisation of
36 spirometry. *Eur Respir J.* 2005;26(2):319-38.
- 37 27. Yang IA, Brown JL, George J, Jenkins S, McDonald CF, McDonald VM, et al. COPD-X Australian
38 and New Zealand guidelines for the diagnosis and management of chronic obstructive
39 pulmonary disease: 2017 update. *Med J Aust.* 2017;207(10):436-42.
- 40 28. Yang IA, Dabscheck E, George J, Jenkins S, McDonald CF, McDonald V, et al. The COPD-X
41 Plan: Australian and New Zealand Guidelines for the management of Chronic Obstructive
42 Pulmonary Disease 2017. Version 2.52. December 2017 2017 [cited 2018 Apr 5].
- 43 29. Zwar N, Richmond R, Borland R, Peters M, Litt J, Bell J, et al. Supporting smoking cessation: a
44 guide for health professionals. Melbourne: The Royal Australian College of General
45 Practitioners; 2011.
- 46 30. Lung Foundation Australia. Better Living with Chronic Obstructive Pulmonary Disease: A
47 Patient Guide. 2nd ed. Queensland: The State of Queensland (Queensland Health) and Lung
48 Foundation Australia; 2012.
- 49 31. Thomas D, Abramson MJ, Bonevski B, Taylor S, Poole S, Weeks GR, et al. A pharmacist-led
50 system-change smoking cessation intervention for smokers admitted to Australian public

- 1 hospitals (GIVE UP FOR GOOD): study protocol for a randomised controlled trial. *Trials*.
2 2013;14:148.
- 3 32. Pharmaceutical Society of Australia. Guidelines for pharmacists providing Home Medicines
4 Review (HMR) services 2011 [cited 2018 Apr 22].
- 5 33. Jones PW, Quirk FH, Baveystock CM, Littlejohns P. A self-complete measure of health status
6 for chronic airflow limitation. The St. George's Respiratory Questionnaire. *Am Rev Respir Dis*.
7 1992;145(6):1321-7.
- 8 34. Jones PW, Harding G, Berry P, Wiklund I, Chen WH, Kline Leidy N. Development and first
9 validation of the COPD Assessment Test. *Eur Respir J*. 2009;34(3):648-54.
- 10 35. Celli BR, Cote CG, Marin JM, Casanova C, Montes de Oca M, Mendez RA, et al. The body-
11 mass index, airflow obstruction, dyspnea, and exercise capacity index in chronic obstructive
12 pulmonary disease. *N Engl J Med*. 2004;350(10):1005-12.
- 13 36. Mahler DA, Wells CK. Evaluation of clinical methods for rating dyspnea. *Chest*.
14 1988;93(3):580-6.
- 15 37. Quanjer PH, Stanojevic S, Cole TJ, Baur X, Hall GL, Culver BH, et al. Multi-ethnic reference
16 values for spirometry for the 3-95-yr age range: the global lung function 2012 equations. *Eur*
17 *Respir J*. 2012;40(6):1324-43.
- 18 38. Snaith RP. The Hospital Anxiety And Depression Scale. *Health Qual Life Outcomes*.
19 2003;1:29.
- 20 39. Zigmond AS, Snaith RP. The hospital anxiety and depression scale. *Acta Psychiatr Scand*.
21 1983;67(6):361-70.
- 22 40. Heatherton TF, Kozlowski LT, Frecker RC, Rickert W, Robinson J. Measuring the heaviness of
23 smoking: using self-reported time to the first cigarette of the day and number of cigarettes
24 smoked per day. *Br J Addict*. 1989;84(7):791-9.
- 25 41. West R, Hajek P, Stead L, Stapleton J. Outcome criteria in smoking cessation trials: proposal
26 for a common standard. *Addiction*. 2005;100(3):299-303.
- 27 42. Adams G, Gulliford MC, Ukoumunne OC, Eldridge S, Chinn S, Campbell MJ. Patterns of intra-
28 cluster correlation from primary care research to inform study design and analysis. *J Clin*
29 *Epidemiol*. 2004;57(8):785-94.
- 30 43. Kruis AL, Smidt N, Assendelft WJ, Gussekloo J, Boland MR, Rutten-van Molken M, et al.
31 Cochrane corner: is integrated disease management for patients with COPD effective?
32 *Thorax*. 2014;69(11):1053-5.
- 33 44. Lipson DA, Barnhart F, Brealey N, Brooks J, Criner GJ, Day NC, et al. Once-Daily Single-Inhaler
34 Triple versus Dual Therapy in Patients with COPD. *N Engl J Med*. 2018.
- 35 45. Alison JA, McKeough ZJ, Johnston K, McNamara RJ, Spencer LM, Jenkins SC, et al. Australian
36 and New Zealand Pulmonary Rehabilitation Guidelines. *Respirology*. 2017;22(4):800-19.
- 37 46. Breitenstein SM, Gross D, Garvey CA, Hill C, Fogg L, Resnick B. Implementation fidelity in
38 community-based interventions. *Res Nurs Health*. 2010;33(2):164-73.

Supplementary Table 1. Quality of life, symptoms and respiratory function at baseline, six and 12 months – ITT with Multiple imputation

Outcome	Within group change at 6 months, mean (95% CI)		Between group difference at 6 months, mean (95% CI) ^b	Within group change at 12 months, mean (95% CI)		Between group difference at 12 months, mean (95% CI) ^b
	Usual care	Intervention		Usual care	Intervention	
SGRQ score ^a	1.25 (-1.38, 3.87)	2.53 (0.20, 4.86)	2.30 (-1.14, 5.75) P = 0.18	4.00 (0.65, 7.35)	4.83 (2.14, 7.52)	1.94 (-2.92, 6.80) P = 0.41
CAT score ^a	1.25 (0.24, 2.26)	1.90 (0.74, 3.05)	0.86 (-1.44, 3.17) P = 0.45	2.87 (1.50, 4.24)	3.03 (1.86, 4.21)	0.64 (-1.99, 3.27) P = 0.62
Post-bronchodilator FEV ₁ , % predicted ^a	-0.16 (-2.26, 1.94)	0.78 (-0.80, 2.36)	1.12 (-1.84, 4.08) P = 0.44	NA	NA	NA

^a Participants with baseline outcome measure included in multiple imputation analysis

^b Adjusted for age, highest education, gross income, current smoking status, existing COPD and clustering

CAT=COPD Assessment Test; CI=Confidence Interval; FEV₁; Forced Expiratory Volume in 1 second; ITT=intention to treat; SGRQ=St George's Respiratory Questionnaire;

Supplementary table 2. Quality of life, symptoms and respiratory function at six and 12 months – Per protocol analysis (PPA)

Outcome	Within group change at 6 months, mean (95% CI)		Between group difference at 6 months, mean (95% CI) ^d	Within group change at 12 months, mean (95% CI)		Between group difference at 12 months, mean (95% CI) ^d
	Usual care (n=115)	Full Intervention (n=49)		Usual care (n=115)	Full Intervention (n=49)	
SGRQ score ^a	1.54 (-1.06, 4.14)	5.66 (1.91, 9.42)	5.22 (0.19, 10.25) P = 0.042	3.35 (0.57, 6.14)	6.67 (1.86, 11.47)	4.02 (-2.19, 10.23) P = 0.20
CAT score ^b	1.50 (0.56, 2.44)	2.87 (1.10, 4.64)	1.49 (-1.37, 4.36) P = 0.30	2.62 (1.58, 3.67)	3.61 (1.36, 5.87)	1.42 (-1.87, 4.71) P = 0.38
Post-bronchodilator FEV ₁ , % predicted ^c	-0.09 (-1.84, 1.67)	1.34 (-1.68, 4.37)	2.03 (-1.73, 5.79) P = 0.28	NA	NA	NA

^a n=157 at baseline, n=137 at 6 months and n= 120 at 12 months respectively.

^b n=163 at baseline, n=140 at 6 months and n= 121 at 12 months respectively.

^c n=162 at baseline and n=125 at 6 months respectively.

^d Adjusted for age, highest education, gross income, current smoking status, existing COPD and clustering

CAT=COPD Assessment Test; CI=Confidence Interval; FEV₁=Forced Expiratory Volume in 1 second; PPA=Per Protocol Analysis; SGRQ=St George's Respiratory Questionnaire

Supplementary table 3. Quality of life, symptoms and respiratory function at six and 12 months – PPA with Multiple Imputation

Outcome	Within group change at 6 months, mean (95% CI)		Between group difference at 6 months, mean (95% CI) ^b	Within group change at 12 months, mean (95% CI)		Between group difference at 12 months, mean (95% CI) ^b
	Usual care (n=115)	Full Intervention (n=49)		Usual care (n=115)	Full Intervention (n=49)	
SGRQ score ^a	1.07 (-1.65, 3.80)	5.53 (1.72, 9.34)	5.34 (0.27, 10.41) P = 0.04	3.97 (0.78, 7.15)	6.52 (1.78, 11.25)	3.50 (-2.09, 9.09) P = 0.21
CAT score ^a	1.30 (0.26, 2.35)	2.86 (1.11, 4.62)	1.60 (-1.18, 4.39) P = 0.25	2.92 (1.76, 4.08)	3.59 (1.46, 5.73)	1.32 (-1.81, 4.44) P = 0.39
Post-bronchodilator FEV ₁ , % predicted ^a	-0.22 (-2.61, 2.18)	1.69 (-1.27, 4.64)	2.29 (-1.63, 6.21) P = 0.24	NA	NA	NA

^a Participants with baseline outcome measure included in multiple imputation analysis

^b Adjusted for age, highest education, gross income, current smoking status, existing COPD and clustering

CAT=COPD Assessment Test; CI=Confidence Interval; FEV₁=Forced Expiratory Volume in 1 second; PPA=Per Protocol Analysis; SGRQ=St George's Respiratory Questionnaire

1. Comparing baseline characteristics of intervention clinics whereby at least one patient received the full intervention vs characteristics of intervention clinics where no patient received the full intervention

Characteristic	Intervention clinics with at least one participant who completed full intervention (n=16)	Intervention clinics with no participant who completed full intervention (n=6)	p-value
Type of practice			1.00
Single GP practice	2 (12.5%)	1 (16.7%)	
Group GP practice/community health centre/interdisciplinary practice	12 (75.0%)	5 (83.3%)	
Community health centre	1 (6.3%)	0 (0.0%)	
Interdisciplinary practice	1 (6.3%)	0 (0.0%)	
Number of GPs, median [IQR]	8 [4.5-12.5]	4 [4-5]	0.053
Number of patients on database, median [IQR]	9657 [7843-43289]	4900 [1182-12160]	0.15
Spirometer available	5 (31.3%)	2 (33.3%)	1.00
Staff training in Smoking cessation in past two years	2 (12.5%)	1 (16.7%)	1.00
Staff training in COPD management in past two years	3 (18.9%)	0 (0%)	0.53
Staff training in Spirometry in past two years	5 (31.3%)	1 (16.7%)	0.63

2. Comparing baseline characteristics of those who completed the trial (i.e. was able to be followed up at 12 months) vs those who dropped out (i.e. was lost to follow-up at 12 months)

Characteristic	Completed trial (n=190)	Did not complete trial (n=82)	p-value^e
Age, mean (SD)	66.0 (10.1)	61.2 (11.6)	0.008
Gender, male	116 (61.1%)	51 (62.2%)	0.87
Born in Australia^a	144 (75.8%)	56 (70.9%)	0.41
Mainly speak English at home	188 (98.9%)	79 (96.3%)	0.16
Education^a			0.16
No formal schooling/up to primary school/primary school	9 (4.7%)	9 (11.4%)	
High school	94 (49.5%)	37 (46.8%)	
Technical/further education	50 (26.3%)	23 (29.1%)	
University education/postgraduate	37 (19.5%)	10 (12.7%)	
Employment status^a			0.54
Employed-full/part-time/casual	50 (26.7%)	26 (31.7%)	
Retired/pensioner	106 (56.7%)	46 (56.1%)	
Unemployed/home duties/student/unable to work/disabled	31 (16.6%)	10 (12.2%)	
Marital status^a			0.002
Married/de-facto/engaged	100 (52.6%)	22 (27.8%)	
Separated/divorced/widowed/never married/single	90 (47.4%)	56 (70.9%)	
Undisclosed	0 (0.0%)	1 (1.3%)	
Current living arrangements^a			0.047
With family/friends/spouse/partner	130 (68.4%)	43 (54.4%)	
Alone at home	56 (29.5%)	31 (39.2%)	

Shared accommodation/community housing/refuge accommodation/residential facility/residential aged care facility	4 (2.1%)	5 (6.3%)	
Average annual household income^b			0.17
<AUD \$30,000	82 (44.3%)	37 (48.7%)	
AUD \$30,000-\$59,999	42 (22.7%)	15 (19.7%)	
AUD \$60,000 or more	41 (22.2%)	8 (10.5%)	
Did not want to disclose	20 (10.8%)	16 (21.1%)	
Previously managed as having COPD	88 (46.3%)	42 (51.2%)	0.41
Currently smoking	112 (58.9%)	54 (65.9%)	0.32
Heaviness of Smoking Index score			0.97
Low nicotine dependence (score 0-2)	31 (27.9%)	14 (27.5%)	
Moderate nicotine dependence (score 3-4)	62 (55.9%)	28 (54.9%)	
High nicotine dependence (score 5-6)	18 (16.2%)	9 (17.6%)	
Post-bronchodilator FEV₁ %predicted, mean (SD)^a	71.9 (19.7)	64.8 (19.8)	0.017
Post-bronchodilator FEV₁ / FVC, mean (SD)^a	0.58 (0.11)	0.55 (0.13)	0.11
Disease severity^a			0.21
Mild	140 (74.1%)	50 (62.5%)	
Moderate	35 (18.5%)	21 (26.3%)	
Severe	14 (7.4%)	9 (11.3%)	
SGRQ score, mean (SD)^c	31.6 (17.3)	33.4 (20.0)	0.45
CAT score, mean (SD)	12.8 (7.4)	14.2 (8.3)	0.15
HADS anxiety score, median [IQR]^d	5 [3-8]	7 [3-10]	0.31
HADS depression score, median [IQR]^d	4 [2-7]	5 [3-7]	0.38
mMRC grade, median [IQR]	1 [0-2]	1 [0-2]	0.72

^aData unavailable for n=3 ^bData unavailable for n=11 ^cData unavailable for n=14 ^dData unavailable for n=8 ^eAll p values are adjusted for clustering effect

3. Comparing baseline characteristics between full intervention group in intervention arm vs those who did not receive full intervention in intervention arm

Characteristic	Full intervention (n=49)	Did not receive full intervention (n=108)	p-value^e
Age, mean (SD)	67.7 (10.1)	66.2 (11.2)	0.43
Gender, male	27 (55.1%)	68 (63.0%)	0.34
Born in Australia^a	38 (77.6%)	76 (72.4%)	0.45
Mainly speak English at home	49 (100.0%)	105 (97.2%)	0.65
Education^a			0.17
No formal schooling/up to primary school/primary school	3 (6.1%)	11 (10.5%)	
High school	19 (38.8%)	49 (46.7%)	
Technical/further education	16 (32.7%)	35 (33.3%)	
University education/postgraduate	11 (22.5%)	10 (9.5%)	
Employment status			0.68
Employed-full/part-time/casual	18 (36.7%)	33 (30.6%)	
Retired/pensioner	25 (51.0%)	59 (54.6%)	
Unemployed/home duties/student/unable to work/disabled	6 (12.2%)	16 (14.8%)	
Marital status^a			0.02
Married/de-facto/engaged	28 (57.1%)	41 (39.1%)	
Separated/divorced/widowed/never married/single	21 (42.9%)	64 (60.9%)	
Current living arrangements^a			0.78
With family/friends/spouse/partner	33 (67.4%)	64 (61.0%)	
Alone at home	16 (32.7%)	35 (33.3%)	

Shared accommodation/community housing/refuge accommodation/residential facility/residential aged care facility	0 (0.0%)	6 (5.7%)	
Average annual household income^b			0.78
<AUD \$30,000	22 (44.9%)	52 (52.0%)	
AUD \$30,000-\$59,999	12 (24.5%)	20 (20.0%)	
AUD \$60,000 or more	10 (20.4%)	21 (21.0%)	
Did not want to disclose	5 (10.2%)	7 (7.0%)	
Previously managed as having COPD	29 (59.2%)	45 (41.7%)	0.06
Currently smoking	22 (44.9%)	62 (57.4%)	0.15
Heaviness of Smoking Index score (current smokers only)			0.98
Low nicotine dependence (score 0-2)	5 (23.8%)	16 (27.1%)	
Moderate nicotine dependence (score 3-4)	12 (57.1%)	32 (54.2%)	
High nicotine dependence (score 5-6)	4 (19.1%)	11 (18.6%)	
Post-bronchodilator FEV₁ %predicted, mean (SD) ^c	68.3(20.6)	69.3 (20.5)	0.75
Post-bronchodilator FEV₁ / FVC, mean (SD) ^c	0.57 (0.14)	0.57 (0.12)	0.93
Disease severity ^c			0.49
Mild	32 (66.7%)	76 (71.0%)	
Moderate	9 (18.8%)	21 (19.6%)	
Severe	7 (14.6%)	10 (9.4%)	
SGRQ score, mean (SD)^b	38.4 (17.8)	29.9 (17.4)	0.004
CAT score, mean (SD)	15.4 (7.7)	11.8 (7.3)	0.002
HADS anxiety score^b, median [IQR]	5 [3-9]	6 [3-9]	0.59
HADS depression score^d, median [IQR]	5 [3-7]	5 [2-7]	0.57
mMRC grade, median [IQR]	1 [1-2]	1 [0-2]	0.10

^aData unavailable for n=3 ^bData unavailable for n=8 ^cData unavailable for n=2 ^dData unavailable for n=6 ^eAll p values are adjusted for clustering effect

4. Comparing baseline respiratory medications in the intervention group only between those who completed HMR vs those who did not complete HMR

Characteristic^a	Did not complete HMR (n=76)	Completed HMR (n=81)	p-value^b
SABA	22 (29.0%)	34 (42.5%)	0.019
SAMA	2 (2.6%)	3 (3.8%)	0.72
ICS alone	3 (4.0%)	2 (2.5%)	0.61
ICS/LABA alone	11 (14.5%)	8 (10.0%)	0.22
LABA/LAMA alone	0 (0%)	2 (2.5%)	0.52
LABA alone	0 (0.0%)	0 (0.0%)	---
LAMA alone	11 (14.5%)	18 (22.5%)	0.20
Triple therapy (ICS & LABA & LAMA)	15 (19.7%)	25 (31.3%)	0.06
Number of non-respiratory medications	3 [2-6]	5 [2-8]	0.12

Medication data was missing for 1 participant


^aData are presented as number(percentage) or median (inter-quartile range)

^bAll p values are adjusted for clustering effect

5. Comparing baseline motivation to quit scores across groups at baseline (for current smokers only)

Characteristic (median [IQR])	Usual care (n=82)	Intervention (n=84)	p-value^b
Motivation to quit (current smokers only)^a	5 [3-8]	6 [3-8]	0.26

^a missing data for 3 participants ^bAll p values are adjusted for clustering effect



*Total of 43 clinics; two clinics belonged to the same consortium where GPs and clinic staff worked across clinics – these clinics were collectively treated as one entity and allocated to the same arm as the clinic initially recruited

†Some participants were available at 6 month follow-up but not available at 12 month follow-up, and vice versa

COPD = chronic obstructive pulmonary disease; GP = general practitioner; HMR = home medicines review; ITT = intention-to-treat

Ethics and role of funding bodies

This project was approved by Monash University Human Research Ethics Committee (CF14/1018 – 2014000433). This trial was funded by the National Health and Medical Research Council (NHMRC) of Australia through the NHMRC Partnership Projects initiative (APP1076255). Cash and/or in-kind contributions were received from partner organisations: Lung Foundation Australia (LFA), Boehringer Ingelheim (BI) Pty Ltd and Eastern Melbourne PHN (EMPHN). The LFA and EMPHN were involved in project design and conduct, and contributed to data interpretation and writing of manuscripts. Boehringer Ingelheim was involved in project discussions, planning and progress review, but had no involvement in the design of the intervention and did not contribute to decisions regarding data analysis and dissemination of findings.

Declarations

All authors had financial and/or in-kind support from the NHMRC, BI, LFA and EMPHN for the submitted work; JG, BB and MJA have held an investigator-initiated grant from Pfizer for unrelated research; JG has received an investigator initiated grant from GRAND, a Pfizer sponsored competitive scheme for promoting tobacco control research, and an honorarium from GSK for consultancy; MJA has received assistance with conference attendance and an honorarium for an unrelated consultancy from Sanofi; JG and NAZ are current members of the Lung Foundation Australia COPD Guidelines Committee; MJA was the Chair of the Committee (2004–14); AEH is a member of the LFA's COPD-X: Concise Guide for Primary Care Advisory Committee; KP is the General Manager of COPD National Program, LFA.